Leadgene Biosolutions, founded in 2018 as Cytena BPS, is a specialist provider of advanced micro‑scale bioprocess technologies, including the C.BIRD, C.NEST 2.0 and S.NEST 2.0 systems. These technologies support early-stage development, cell culture optimisation and data-driven bioprocess decision making. In 2025, the company transitioned into an independent identity through integration with Leadgene Biomedical, uniting academic innovation, international experience, and real-world insight within a unified biosolutions organisation.

BPES is proud to partner with Leadgene Biosolutions, bringing these systems to UK researchers for high-quality, reproducible data generation and early-stage bioprocess development.

Bringing Innovation to Early-Stage Bioprocessing

Leadgene systems bridge the gap between small-scale experiments and larger-scale bioprocesses. By providing high-throughput, process-relevant culture conditions, these instruments allow scientists to generate reliable data that informs later-stage development.

Key Features of Leadgene Technologies

Leadgene’s systems are distinguished by their patented pneumatic mixing technology, which improves nutrient distribution and oxygen transfer in multi-well culture formats, enhancing the uniformity and reproducibility of experiments. The S.NEST system also provides real-time pH and dissolved oxygen (DO) monitoring, giving researchers greater insight into culture conditions. Both C.NEST 2.0 and S.NEST 2.0 offer optional UV sterilisation to maintain aseptic conditions. Across all systems, easy, intuitive software allows users to efficiently manage complex experiments and capture reliable, reproducible data. These features collectively support accelerated early-stage development and more informed decision-making in cell line development workflows.

Why This Partnership Matters

BPES has always ensured UK researchers have access to leading-edge bioprocess tools. The addition of Leadgene’s systems strengthens our cell line development portfolio, enabling earlier identification of top-producing clones, generation of process-relevant data, and increased efficiency in early-stage bioprocess development.

This partnership adds powerful new capabilities to BPES’s CLD offering, giving UK researchers access to innovative micro-scale systems that enhance reproducibility, accelerate early-stage development, and improve decision-making across cell line selection and bioprocess workflows.

With these systems, BPES continues to help scientists generate high-quality, reproducible data and make faster, more informed decisions in CLD and early-stage bioprocessing.

For more information on Leadgene Biosolutions and their systems, visit: https://bioprocess-eng.co.uk/suppliers/leadgene-biosolutions/